The immunological footprint of mycobacterium tuberculosis t-cell epitope recognition

Journal of Infectious Diseases

Volumn 205, Issue SUPPL. 2, 2012, Pages

  Axelsson Robertson, Rebecca ^a   Magalhaes, Isabelle ^b   Parida, Shreemanta K ^c   Zumla, Alimuddin ^d   Maeurer, Markus ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c DEPARTMENT OF BIOTECHNOLOGY   (India)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; EPITOPE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELLULAR IMMUNITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMMUNOGENICITY; IMMUNOLOGY; INFECTION RISK; INNATE IMMUNITY; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; SERODIAGNOSIS; T LYMPHOCYTE;

BIOLOGICAL MARKERS; EPITOPES, T-LYMPHOCYTE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY;

EID: 84860361345     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis198     Document Type: Review

References (149)

1. WHO global tuberculosis control report 2010. Summary. Cent Eur J Public Health 2010; 18:237.
2. Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11:343-54.
3. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375:1920-37.
4. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717-25.
5. Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD81 T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009; 119:1167-77.
6. Henderson RA, Watkins SC, Flynn JL. Activation of human dendritic cells following infection with Mycobacterium tuberculosis. J Immunol 1997; 159:635-43.
7. Cosma CL, Humbert O, Ramakrishnan L. Superinfecting mycobacteria home to established tuberculous granulomas. Nat Immunol 2004; 5:828-35.
8. Ulrichs T, Kosmiadi GA, Trusov V, et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004; 204:217-28.
9. Lay G, Poquet Y, Salek-Peyron P, et al. Langhans giant cells from M. tuberculosis-induced human granulomas cannot mediate mycobacterial uptake. J Pathol 2007; 211:76-85.
10. Bermudez LE, Goodman J. Mycobacterium tuberculosis invades and replicates within type II alveolar cells. Infect Immun 1996; 64:1400-6.
11. Kim JS, Ryu MJ, Byun EH, et al. Differential immune response of adipocytes to virulent and attenuated Mycobacterium tuberculosis. Microbes Infect 2011; 13:1242-51.
12. Dirat B, Bochet L, Dabek M, et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 2011; 71:2455-65.
13. Meijer K, de Vries M, Al-Lahham S, et al. Human primary adipocytes exhibit immune cell function: adipocytes prime inflammation independent of macrophages. PLoS One 2011; 6:e17154.
14. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11:85-97.
15. Opie EL, Aronson JD. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions*. Arch Pathol 1927; 4:1-21.
16. Hernandez-Pando R, Jeyanathan M, Mengistu G, et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000; 356:2133-8.
17. Bishai WR. Rekindling old controversy on elusive lair of latent tuberculosis. Lancet 2000; 356:2113-14.
18. den Boer AT, Diehl L, van Mierlo GJ, et al. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol 2001; 167:2522-8.
19. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153:5586-92.
20. Bihl F, Frahm N, Di Giammarino L, et al. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol 2006; 176:4094-101.
21. Bertoletti A, Sette A, Chisari FV, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994; 369:407-10.
22. Klenerman P, Rowland-Jones S, McAdam S, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 1994; 369:403-7.
23. Kersh GJ, Kersh EN, Fremont DH, Allen PM. High-and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity 1998; 9:817-26.
24. Huang J, Zarnitsyna VI, Liu B, et al. The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. Nature 2010; 464:932-6.
25. Prlic M, Hernandez-Hoyos G, Bevan MJ. Duration of the initial TCR stimulus controls the magnitude but not functionality of the CD81 T cell response. J Exp Med 2006; 203:2135-43.
26. Galea I, Stasakova J, Dunscombe MS, Ottensmeier CH, Elliott T, Thirdborough SM. CD8(1) T-cell cross-competition is governed by peptide-MHC class I stability. Eur J Immunol 2011; 42:256-63.
27. Rechtsteiner G, Warger T, Hofmann M, Rammensee HG, Schild H, Radsak MP. Precursor frequency can compensate for lower TCR expression in T cell competition during priming in vivo. Eur J Immunol 2006; 36:2613-23.
28. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003; 18:255-64.
29. Kerry SE, Buslepp J, Cramer LA, et al. Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J Immunol 2003; 171: 4493-503.
30. Siew LK, Beech JT, Thompson SJ, Elson CJ. Effect of T-helper cytokine environment on specificity of T-cell responses to mycobacterial 65,000 MW heat-shock protein. Immunology 1998; 93:493-7.
31. Ulrichs T, Munk ME, Mollenkopf H, et al. Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur J Immunol 1998; 28:3949-58.
32. Silver RF, Wallis RS, Ellner JJ. Mapping of T cell epitopes of the 30-kDa alpha antigen of Mycobacterium bovis strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. J Immunol 1995; 154:4665-74.
33. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393:537-44.
34. Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection. J Clin Microbiol 2004; 42:2379-87.
35. Axelsson-Robertson R, Weichold F, Sizemore D, et al. Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses. Immunology 2010; 129:496-505.
36. Mustafa AS. Recombinant and synthetic peptides to identify Mycobacterium tuberculosis antigens and epitopes of diagnostic and vaccine relevance. Tuberculosis (Edinb) 2005; 85:367-76.
37. Hammond AS, Klein MR, Corrah T, et al. Mycobacterium tuberculosis genome-wide screen exposes multiple CD8 T cell epitopes. Clin Exp Immunol 2005; 140:109-16.
38. McMurry JA, Kimball S, Lee JH, et al. Epitope-driven TB vaccine development: a streamlined approach using immuno-informatics, ELISpot assays, and HLA transgenic mice. Curr Mol Med 2007; 7: 351-68.
39. Vita R, Zarebski L, Greenbaum JA, et al. The immune epitope database 2.0. Nucleic Acids Res 2010; 38:D854-62.
40. Camus JC, Pryor MJ, Medigue C, Cole ST. Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 2002; 148:2967-73.
41. Arend SM, Geluk A, van Meijgaarden KE, et al. Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides. Infect Immun 2000; 68: 3314-21.
42. Mustafa AS, Oftung F, Amoudy HA, et al. Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines. Clin Infect Dis 2000; 30(Suppl 3): S201-5.
43. Weichold FF, Mueller S, Kortsik C, et al. Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD81 T-cell response in patients with pulmonary tuberculosis. Genes Immun 2007; 8:334-43.
44. Skjot RL, Brock I, Arend SM, et al. Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 2002; 70:5446-53.
45. Mustafa AS, Al-Attiyah R, Hanif SN, Shaban FA. Efficient testing of large pools of Mycobacterium tuberculosis RD1 peptides and identification of major antigens and immunodominant peptides recognized by human Th1 cells. Clin Vaccine Immunol 2008; 15:916-24.
46. Chaitra MG, Shaila MS, Nayak R. Detection of interferon gammasecreting CD81 T lymphocytes in humans specific for three PE/PPE proteins of Mycobacterium tuberculosis. Microbes Infect 2008; 10:858-67.
47. Blythe MJ, Zhang Q, Vaughan K, et al. An analysis of the epitope knowledge related to mycobacteria. Immunome Res 2007; 3:10.
48. Reddy TB, Riley R, Wymore F, et al. TB database: an integrated platform for tuberculosis research. Nucleic Acids Res 2009; 37:D499-508.
49. Natarajan K, Latchumanan VK, Singh B, Singh S, Sharma P. Downregulation of T helper 1 responses to mycobacterial antigens due to maturation of dendritic cells by 10-kDa Mycobacterium tuberculosis secretory antigen. J Infect Dis 2003; 187:914-28.
50. Ganguly N, Giang PH, Gupta C, et al. Mycobacterium tuberculosis secretory proteins CFP-10, ESAT-6 and the CFP10:ESAT6 complex inhibit lipopolysaccharide-induced NF-kappaB transactivation by downregulation of reactive oxidative species (ROS) production. Immunol Cell Biol 2008; 86:98-106.
51. Black GF, Thiel BA, Ota MO, et al. Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 2009; 16:1203-12.
52. Schuck SD, Mueller H, Kunitz F, et al. Identification of T-cell antigens specific for latent Mycobacterium tuberculosis infection. PLoS One 2009; 4:e5590.
53. Gideon HP, Wilkinson KA, Rustad TR, et al. Hypoxia induces an immunodominant target of tuberculosis specific T cells absent from common BCG vaccines. PLoS Pathog 2010; 6:e1001237.
54. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database:. http://www.allelefrequencies.net. Tissue Antigens 2003; 61:403-7.
55. Kumar M, Sundaramurthi JC, Mehra NK, Kaur G, Raja A. Cellular immune response to Mycobacterium tuberculosis-specific antigen culture filtrate protein-10 in south India. Med Microbiol Immunol 2010; 199:11-25.
56. Mustafa AS, Shaban F. Mapping of Th1-cell epitope regions of Mycobacterium tuberculosis protein MPT64 (Rv1980c) using synthetic peptides and T-cell lines from M. tuberculosis-infected healthy humans. Med Princ Pract 2010; 19:122-8.
57. Comas I, Chakravartti J, Small PM, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010; 42:498-503.
58. Hohn H, Kortsik C, Tully G, et al. Longitudinal analysis of Mycobacterium tuberculosis 19-kDa antigen-specific T cells in patients with pulmonary tuberculosis: association with disease activity and crossreactivity to a peptide from HIVenv gp120. Eur J Immunol 2003; 33:1613-23.
59. Stead WW, Senner JW, Reddick WT, Lofgren JP. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med 1990; 322:422-7.
60. Spence DP, Hotchkiss J, Williams CS, Davies PD. Tuberculosis and poverty. BMJ 1993; 307:759-61.
61. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004; 8:286-98.
62. Malhotra I, Mungai P, Wamachi A, et al. Helminth-and bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 1999; 162:6843-8.
63. Moller M, Nebel A, Valentonyte R, van Helden PD, Schreiber S, Hoal EG. Investigation of chromosome 17 candidate genes in susceptibility to TB in a South African population. Tuberculosis (Edinb) 2009; 89: 189-94.
64. Pacheco AG, Cardoso CC, Moraes MO. IFNG 1874T/A, IL10-1082G/A and TNF-308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum Genet 2008; 123:477-84.
65. Olesen R, Wejse C, Velez DR, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun 2007; 8:456-67.
66. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol 1999; 163:3920-7.
67. Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One 2007; 2:e1318.
68. Brahmajothi V, Pitchappan RM, Kakkanaiah VN, et al. Association of pulmonary tuberculosis and HLA in south India. Tubercle 1991; 72:123-32.
69. Khomenko AG, Litvinov VI, Chukanova VP, Pospelov LE. Tuberculosis in patients with various HLA phenotypes. Tubercle 1990; 71:187-92.
70. Ruggiero G, Cosentini E, Zanzi D, et al. Allelic distribution of human leucocyte antigen in historical and recently diagnosed tuberculosis patients in southern Italy. Immunology 2004; 111:318-22.
71. Lewinsohn DA, Winata E, Swarbrick GM, et al. Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 2007; 3:1240-9.
72. Kiepiela P, Leslie AJ, Honeyborne I, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-75.
73. Lacey SF, Villacres MC, La Rosa C, et al. Relative dominance of HLAB* 07 restricted CD81 T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 2003; 64:440-52.
74. Frahm N, Yusim K, Suscovich TJ, et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007; 37: 2419-33.
75. Shingler WH, Chikoti P, Kingsman SM, Harrop R. Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4. Int Immunol 2008; 20:1057-66.
76. Harding CV, Boom WH. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol 2010; 8:296-307.
77. Baena A, Porcelli SA. Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens 2009; 74: 189-204.
78. Woodworth JS, Behar SM. Mycobacterium tuberculosis-specific CD81 T cells and their role in immunity. Crit Rev Immunol 2006; 26: 317-52.
79. Woodworth JS, Fortune SM, Behar SM. Bacterial protein secretion is required for priming of CD81 T cells specific for the Mycobacterium tuberculosis antigen CFP10. Infect Immun 2008; 76:4199-205.
80. Grotzke JE, Siler AC, Lewinsohn DA, Lewinsohn DM. Secreted immunodominant Mycobacterium tuberculosis antigens are processed by the cytosolic pathway. J Immunol 2010; 185:4336-43.
81. van der Wel N, Hava D, Houben D, et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 2007; 129:1287-98.
82. Schaible UE, Winau F, Sieling PA, et al. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 2003; 9:1039-46.
83. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol 2010; 11:751-8.
84. Lv Y, Yan B, Yang H, et al. LMP2/LMP7 gene variant: a risk factor for intestinal Mycobacterium tuberculosis infection in the Chinese population. J Gastroenterol Hepatol 2011; 26:1145-50.
85. O'Leary S, O'Sullivan MP, Keane J. IL-10 blocks phagosome maturation in Mycobacterium tuberculosis-infected human macrophages. Am J Respir Cell Mol Biol 2011; 45:172-80.
86. Rosat JP, Grant EP, Beckman EM, et al. CD1-restricted microbial lipid antigen-specific recognition found in the CD81 alpha beta T cell pool. J Immunol 1999; 162:366-71.
87. Shen Y, Zhou D, Qiu L, et al. Adaptive immune response of Vgamma2Vdelta21 T cells during mycobacterial infections. Science 2002; 295:2255-8.
88. Wei H, Huang D, Lai X, et al. Definition of APC presentation of phosphoantigen (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate to Vgamma2Vdelta 2 TCR. J Immunol 2008; 181:4798-806.
89. Gioia C, Agrati C, Goletti D, et al. Different cytokine production and effector/memory dynamics of alpha beta1 or gamma delta1 T-cell subsets in the peripheral blood of patients with active pulmonary tuberculosis. Int J Immunopathol Pharmacol 2003; 16:247-52.
90. Dieli F, Troye-Blomberg M, Ivanyi J, et al. Granulysin-dependent killing of intracellular and extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T lymphocytes. J Infect Dis 2001; 184:1082-5.
91. Sarikonda G, Wang H, Puan KJ, et al. Photoaffinity antigens for human gammadelta T cells. J Immunol 2008; 181:7738-50.
92. Vankayalapati R, Garg A, Porgador A, et al. Role of NK cell-activating receptors and their ligands in the lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 2005; 175: 4611-7.
93. Dhiman R, Indramohan M, Barnes PF, et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 2009; 183:6639-45.
94. Schierloh P, Yokobori N, Aleman M, et al. Increased susceptibility to apoptosis of CD56dimCD161 NK cells induces the enrichment of IFN-gamma-producing CD56bright cells in tuberculous pleurisy. J Immunol 2005; 175:6852-60.
95. Vankayalapati R, Klucar P, Wizel B, et al. NK cells regulate CD81 T cell effector function in response to an intracellular pathogen. J Immunol 2004; 172:130-7.
96. Eum SY, Kong JH, Hong MS, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 2010; 137:122-8.
97. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colonystimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194:519-27.
98. Cruz A, Fraga AG, Fountain JJ, et al. Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 2010; 207: 1609-16.
99. McNab FW, Berry MP, Graham CM, et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol 2011; 41:1941-7.
100. Seiler P, Aichele P, Bandermann S, et al. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3-signaling chemokines. Eur J Immunol 2003; 33:2676-86.
101. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466:973-7.
102. Blomgran R, Ernst JD. Lung neutrophils facilitate activation of naive antigen-specific CD41 T cells during Mycobacterium tuberculosis infection. J Immunol 2011; 186:7110-19.
103. Jafari C, Ernst M, Strassburg A, et al. Local immunodiagnosis of pulmonary tuberculosis by enzyme-linked immunospot. Eur Respir J 2008; 31:261-5.
104. Rieder HL. Epidemiologic basis of tuberculosis control. International Union Against Tuberculosis and Lung Disease. 1st ed. 1999.
105. Vukmanovic-Stejic M, Agius E, Booth N, et al. The kinetics of CD41Foxp31 T cell accumulation during a human cutaneous antigen-specific memory response in vivo. J Clin Invest 2008; 118: 3639-50.
106. Reed JR, Vukmanovic-Stejic M, Fletcher JM, et al. Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med 2004; 199:1433-43.
107. Tomlinson GS, Cashmore TJ, Elkington PT, et al. Transcriptional profiling of innate and adaptive human immune responses to mycobacteria in the tuberculin skin test. Eur J Immunol 2011; 41:3253-60.
108. Lohiya GS, Lilia TF, Krishna V. Interpretation of the tuberculin skin test. J Natl Med Assoc 2009; 101:282-3.
109. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immunebased diagnosis of tuberculosis. Lancet 2000; 356:1099-104.
110. Aagaard C, Brock I, Olsen A, Ottenhoff TH, Weldingh K, Andersen P. Mapping immune reactivity toward Rv2653 and Rv2654: two novel low-molecular-mass antigens found specifically in the Mycobacterium tuberculosis complex. J Infect Dis 2004; 189:812-9.
111. Diel R, Goletti D, Ferrara G, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37:88-99.
112. European Center for Disease Prevention and Control Guidance. Use of interferon-gamma release assays in support of TB diagnosis. 2011.
113. Harari A, Rozot V, Enders FB, et al. Dominant TNF-alpha1 Mycobacterium tuberculosis-specific CD41 T cell responses discriminate between latent infection and active disease. Nat Med 2011; 17:372-6.
114. Day CL, Abrahams DA, Lerumo L, et al. Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load. J Immunol 2011; 187:2222-32.
115. Sester U, Fousse M, Dirks J, et al. Whole-blood flow-cytometric analysis of antigen-specific CD4 T-cell cytokine profiles distinguishes active tuberculosis from non-active states. PLoS One 2011; 6:e17813.
116. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009; 39:723-9.
117. Caccamo N, Guggino G, Joosten SA, et al. Multifunctional CD4(1) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 2010; 40:2211-20.
118. Smith SM, Brookes R, Klein MR, et al. Human CD81CTL specific for the mycobacterial major secreted antigen 85A. J Immunol 2000; 165:7088-95.
119. Caccamo N, Meraviglia S, La Mendola C, Guggino G, Dieli F, Salerno A. Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J Immunol 2006; 177:1780-5.
120. Klein MR, Smith SM, Hammond AS, et al. HLA-B*35-restricted CD8 T cell epitopes in the antigen 85 complex of Mycobacterium tuberculosis. J Infect Dis 2001; 183:928-34.
121. Geluk A, van Meijgaarden KE, Franken KL, et al. Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD81 T cells in HLAtransgenic mice and humans. J Immunol 2000; 165:6463-71.
122. Caccamo N, Guggino G, Meraviglia S, et al. Analysis of Mycobacterium tuberculosis-specific CD8 T cells in patients with active tuberculosis and in individuals with latent infection. PLoS One 2009; 4:e5528.
123. Hohn H, Julch M, Pilch H, et al. Definition of the HLA-A2 restricted peptides recognized by human CD81 effector T cells by flow-assisted sorting of the CD81 CD45RA1 CD28-T cell subpopulation. Clin Exp Immunol 2003; 131:102-10.
124. Hohn H, Kortsik C, Zehbe I, et al. MHC class II tetramer guided detection of Mycobacterium tuberculosis-specific CD41 T cells in peripheral blood from patients with pulmonary tuberculosis. Scand J Immunol 2007; 65:467-78.
125. Li Y, Zhu Y, Zhou L, et al. Use of HLA-DR*08032/E7 and HLADR* 0818/E7 tetramers in tracking of epitope-specific CD41 T cells in active and convalescent tuberculosis patients compared with control donors. Immunobiology 2011; 216:947-60.
126. Bronke C, Palmer NM, Westerlaken GH, et al. Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus-and Mycobacterium tuberculosis-specific CD41 T cells. Hum Immunol 2005; 66:950-61.
127. Tang ST, van Meijgaarden KE, Caccamo N, et al. Genome-based in silico identification of new Mycobacterium tuberculosis antigens activating polyfunctional CD81 T cells in human tuberculosis. J Immunol 2011; 186:1068-80.
128. Axelsson-Robertson R, Ahmed RK, Weichold FF, et al. Human leukocyte antigens A*3001 and A*3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition. Clin Vaccine Immunol 2011; 18: 125-34.
129. van der Burg SH, Kalos M, Gouttefangeas C, et al. Harmonization of immune biomarker assays for clinical studies. Sci Transl Med 2011; 3:108ps44.
130. Tully G, Kortsik C, Hohn H, et al. Highly focused T cell responses in latent human pulmonary Mycobacterium tuberculosis infection. J Immunol 2005; 174:2174-84.
131. Kasmar AG, van Rhijn I, Cheng TY, et al. CD1b tetramers bind {alpha}{beta} T cell receptors to identify a mycobacterial glycolipidreactive T cell repertoire in humans. J Exp Med 2011; 208:1741-7.
132. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12.
133. Kohlmeier JE, Reiley WW, Perona-Wright G, et al. Inflammatory chemokine receptors regulate CD81 T cell contraction and memory generation following infection. J Exp Med 2011; 208:1621-34.
134. Souza AL, Souza PR, Pereira CA, et al. Experimental infection with Schistosoma mansoni in CCR5-deficient mice is associated with increased disease severity, as CCR5 plays a role in controlling granulomatous inflammation. Infect Immun 2011; 79:1741-9.
135. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
136. de la Barrera S, Aleman M, Musella R, et al. IL-10 down-regulates costimulatory molecules on Mycobacterium tuberculosis-pulsed macrophages and impairs the lytic activity of CD4 and CD8 CTL in tuberculosis patients. Clin Exp Immunol 2004; 138:128-38.
137. Gehring AJ, Rojas RE, Canaday DH, Lakey DL, Harding CV, Boom WH. The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2. Infect Immun 2003; 71:4487-97.
138. Tobian AA, Potter NS, Ramachandra L, et al. Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling pathogen-associated molecular patterns: Mycobacterium tuberculosis 19-kDa lipoprotein, CpG DNA, and lipopolysaccharide. J Immunol 2003; 171:1413-22.
139. Pai RK, Convery M, Hamilton TA, Boom WH, Harding CV. Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J Immunol 2003; 171:175-84.
140. Castelli C, Maeurer MJ. The T-cell response in patients with cancer. Adv Cancer Res 2002; 86:149-93.
141. Lurquin C, Lethe B, De Plaen E, et al. Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005; 201:249-57.
142. Lonchay C, van der Bruggen P, Connerotte T, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004; 101(Suppl 2):14631-8.
143. Corbiere V, Chapiro J, Stroobant V, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res 2011; 71:1253-62.
144. Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol 1998; 6:107-12.
145. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7:845-55.
146. Gagneux S, Small PM. Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development. Lancet Infect Dis 2007; 7:328-37.
147. Caws M, Thwaites G, Dunstan S, et al. The influence of host and bacterial genotype on the development of disseminated disease with Mycobacterium tuberculosis. PLoS Pathog 2008; 4:e1000034.
148. Al-Hajoj SA, Akkerman O, Parwati I, et al. Microevolution of Mycobacterium tuberculosis in a tuberculosis patient. J Clin Microbiol 2010; 48:3813-16.
149. Kaufmann SH, Parida SK. Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe 2008; 4:219-28.